Social network
Investors - Ensuring sustainable growth
Investors - Ensuring sustainable growth

Investors

Ensuring sustainable growth

Tools content (print, share, increase/decrease text size):

 

Dupixent® FDA approval call

March 28, 2017

Sanofi and Regeneron hosted a conference call & webcast following the approval of Dupixent® for the treatment of adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD), a serious, chronic inflammatory skin disease.

 

Conference Call Replay:

US: +1 (855) 859-2056
International: +1 (404) 537-3406

Conference ID: 92138426

 

Right area:

Stock Market

IR mobile application

SANOFI IR - The Investor Relations Mobile Application

SANOFI IR is available on iPhone, iPad, Apple Watch and Android!
NEW - Section dedicated to Individual Shareholders

 

Your services

 

© Sanofi 2004-2017 - All rights reserved - Update: April 03, 2017

  • Site complies with W3C WCAG 2.0 (new window, in english)